BLOG — Saisei Mirai

The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 PatientsPreprints with The Lancet 19 Pages Posted: 7 Feb 2023 Abstract BACKGROUND: Excessive inflammation and lymphopenia are linked to poor Covid-19 clinical outcomes. Targeting both conditions using an immunomodulating approach needs to be tested.METHODS: We conducted an open-label, randomized, controlled trial of MAF Capsules and M Capsules in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection but at enrolment did not require resuscitation or mechanical ventilation. Patients were randomly assigned to receive, in addition to standard of care...

  The key concept of cancer therapy is the destruction of local cancer tissue in combination with immunotherapy. It is important that we destroy local cancer tissue with minimal side effects and kill cancer cells selectively. In this meaning, Sondynamic therapy, Ultrasound guided HIFU and Tumor-treating field therapy in combination with GcMAF based Immunotherapy seem to be very promising.

Saisei Mirai has developed the 2nd and 3rd Generation GcMAF in Japan. We hold worldwide patents. We have clinics in Osaka, Kobe, and Tokyo.  Our head office and cell processing center are in Osaka.     We have been mainly treating cancer patients in the past, but we now treat patients with a wide variety of diseases from all over the world.   Saisei Mirai is expanding overseas and now has several branches around the world. Our goal is to help cure serious diseases, such as cancer, autism, and infectious diseases.   Saisei Mirai is conducting joint research with 6 universities...